Standard-Intensity Versus Low-Intensity Anticoagulation with Warfarin in Asian Patients with Atrial Fibrillation: A Multi-Center, Randomized Controlled Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Jeong Gwan | - |
dc.contributor.author | Lee, Ki Hong | - |
dc.contributor.author | Kim, Yoo Ri | - |
dc.contributor.author | Kim, Sunah | - |
dc.contributor.author | Gwak, Jisoo | - |
dc.contributor.author | Cho, Eunbit | - |
dc.contributor.author | Sin, Yourim | - |
dc.contributor.author | Shin, Seung Yong | - |
dc.contributor.author | Park, Hyung Wook | - |
dc.contributor.author | Ko, Jum Suk | - |
dc.contributor.author | Kim, Nam Ho | - |
dc.contributor.author | Park, Yae Min | - |
dc.contributor.author | Lee, Jung Myung | - |
dc.contributor.author | Yoon, Nam Sik | - |
dc.contributor.author | Kim, Sung Soo | - |
dc.contributor.author | Kim, Jun Hyung | - |
dc.contributor.author | Kim, Dong Min | - |
dc.date.accessioned | 2023-05-17T00:41:05Z | - |
dc.date.available | 2023-05-17T00:41:05Z | - |
dc.date.created | 2023-05-15 | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1076-0296 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87783 | - |
dc.description.abstract | Anticoagulation with warfarin in Asian patients with atrial fibrillation (AF) often has been decreased as an international normalized ratio (INR) of prothrombin time 1.6-2.6 due to fear of bleeding, although universal criteria recommend an INR of 2.0-3.0. In this randomized, open-label trial, low-intensity anticoagulation (INR 1.6-2.6) was compared with standard-intensity anticoagulation (INR 2.0-3.0) with warfarin. A total 616 patients with AF and at least 1 risk factor for stroke were randomized to low-intensity anticoagulation (n = 308) and standard-intensity anticoagulation (n = 308) groups. The intention-to-treat analysis was performed to determine differences. The baseline characteristics of the two groups were comparable. New-onset stroke occurred in 2 patients (0.44% per year) in the low-intensity group and 5 patients (1.05% per year) in the standard-intensity group (HR 0.42, 95% CI 0.08-2.15). Major bleeding occurred in 4 patients (0.89% per year) in the low-intensity group and 5 patients (1.06% per year) in the standard-intensity group (HR 0.84, 95% CI 0.22-3.11). The rate of the net clinical outcome (composite of stroke, systemic embolism, major bleeding, and death) was 1.33% per year in the low-intensity group compared with 2.12% per year in the standard-intensity group (HR 0.63, 95% CI 0.23-1.72). In Asian patients with AF, clinical outcomes were not different between low-intensity and standard-intensity anticoagulation with warfarin. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS INC | - |
dc.relation.isPartOf | CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | - |
dc.title | Standard-Intensity Versus Low-Intensity Anticoagulation with Warfarin in Asian Patients with Atrial Fibrillation: A Multi-Center, Randomized Controlled Trial | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000973182600001 | - |
dc.identifier.doi | 10.1177/10760296231171081 | - |
dc.identifier.bibliographicCitation | CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, v.29 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.scopusid | 2-s2.0-85153422265 | - |
dc.citation.title | CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS | - |
dc.citation.volume | 29 | - |
dc.contributor.affiliatedAuthor | Park, Yae Min | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | warfarin | - |
dc.subject.keywordAuthor | prothrombin time | - |
dc.subject.keywordAuthor | atrial fibrillation | - |
dc.subject.keywordAuthor | thromboembolism | - |
dc.subject.keywordAuthor | safety | - |
dc.subject.keywordPlus | INTERNATIONAL NORMALIZED RATIO | - |
dc.subject.keywordPlus | SECONDARY PREVENTION | - |
dc.subject.keywordPlus | JAPANESE PATIENTS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | SUBANALYSIS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | STROKE | - |
dc.subject.keywordPlus | PHARMACOTHERAPY | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.